Gufic Biosciences Navigates Growth with Strategic Shifts and Indore Ramp-Up in Q3 FY26

Gufic Biosciences Limited reported a total revenue of INR 231.1 crores for Q3 FY26, marking a nearly flat performance compared to the previous quarter's INR 230.4 crores. Despite expectations for a more significant rise, the company's EBITDA stood at INR 37.1 crores, with margins at 16.05%. Profit After Tax (PAT) for the quarter was INR 15.6 crores, reflecting a PAT margin of 6.75%. The management attributed the subdued growth to strategic internal realignments, particularly addressing working capital challenges in its domestic business segments. This quarter's performance underscores a period of deliberate consolidation and foundational strengthening, especially with the ongoing ramp-up of its new Indore manufacturing facility.

The company's revenue streams are diversified across several key segments. Domestic Business contributed approximately 50% of the total revenue, amounting to INR 115.55 crores. International Business followed with about 25%, or INR 57.78 crores, showcasing significant growth momentum. Contract Manufacturing Organization (CMO) services accounted for roughly 15% (INR 34.67 crores), while Bulk Drugs & API made up the remaining 10% (INR 23.11 crores). Management noted that while domestic business growth was around 8%, the international business saw almost 40% growth, albeit on a lower base. The CMO business remained relatively stable, with capacity increasingly being utilized for export orders, reflecting a strategic shift in resource allocation.

Strategic Realignment and Operational Progress

A significant development this quarter was the management's decision to course-correct its domestic billing strategy for Critical Care and Sparsh divisions. Previously, the company adopted a direct-to-hospital approach, which led to stretched working capital and longer payment cycles, with debtors reaching around INR 320 crores against an INR 800 crore turnover last year. To mitigate this, Gufic Biosciences is transitioning back to a stockist-billing model. This strategic shift, while incurring a short-term hit of INR 14-16 crores in Q3 FY26, is aimed at improving cash flow and reducing debtor days from 140 to an expected 120 days in FY26. This move demonstrates management's commitment to disciplined working capital management and long-term financial health.

The Indore manufacturing facility continues to be a cornerstone of Gufic's growth strategy. The facility, designed to meet global regulatory standards including WHO GMP, EU GMP, ANVISA, MHRA, and USFDA, commenced production in October 2024. A crucial milestone was achieved with the completion of the EU GMP audit in December 2025, paving the way for market access in Europe. Management projects the Indore plant to reach 30% utilization and achieve EBIDTA breakeven by FY26, becoming margin accretive by FY27. This expansion is vital for scaling up complex injectable manufacturing and supporting the company's international ambitions.

International Expansion and Innovation Pipeline

Gufic Biosciences is actively pursuing an IP-controlled, complex injectable-led export and licensing model for its international business. Recent regulatory progress includes colistimethate approval in Germany and continuity actions for Pantoprazole injection in Portugal and Vancomycin Injection in Lithuania. The company also expanded registrations in Myanmar across various product baskets and secured Unit-2 GMP approval in Oman, opening doors to the lucrative Middle East market. The international business is expected to be a significant growth driver, with export revenues from Indore anticipated to kick in from Q3/Q4 FY26 for regulated markets.

Innovation remains a key focus, with robust R&D efforts in peptides, dual-chamber syringes, and API development. The company is advancing its immuno-oncology therapy, SVX-3001, a humanized anti-CD40 agonist antibody, which has shown promising preclinical results in converting 'cold' tumors to 'hot' tumors. Additionally, Gufic is developing innovative Botulinum Toxin formulations and expanding its portfolio in new therapy areas like Biologicals and Immuno-Oncology, signaling a forward-looking approach to healthcare advancements.

Outlook and Investor Confidence

Looking ahead, Gufic Biosciences aims for a minimum of 15% revenue growth in FY27, driven by the ramp-up of the Indore facility and improved working capital efficiency. EBITDA margins are projected to improve from the current 16% to 19% as Indore's utilization crosses 50%, potentially reaching 20-21% at over 75% utilization. The company's disciplined approach to managing debt, prioritizing internal accruals for growth, and strategic investments in high-value segments reinforces its commitment to sustainable growth. Despite short-term adjustments, Gufic Biosciences is strategically positioning itself for long-term value creation through enhanced manufacturing capabilities, a robust R&D pipeline, and expanded global market presence.